Search - tctmd.com

Displaying 1 - 20 of 85

Sort: Relevancy | Date

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

Statin Therapy Still Lacking for Many US Patients With ASCVD

News Daily News

Statin Therapy Still Lacking for Many US Patients With ASCVD

August 07, 2023

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

July 11, 2023

For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI

News Daily News

For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI

Michael O'Riordan

February 23, 2023

Good News and Bad for High-Intensity Statin Use in ASCVD

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

Statins Underprescribed in PAD Before and After Interventions

News Daily News

Statins Underprescribed in PAD Before and After Interventions

December 03, 2021

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

News Daily News

Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups

February 01, 2021

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

August 12, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Outcome Differences Between Men and Women With PAD: EUCLID Insights

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

February 11, 2020

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

TCTMD’s Top 10 Most Popular Stories for August 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

August 30, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

TAVR Bleeds Stand Apart From PCI-Related Events

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

August 06, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.